Insulet Corporation $PODD Stock Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 167.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,236 shares of the medical instruments supplier’s stock after acquiring an additional 18,293 shares during the period. Fulcrum Asset Management LLP’s holdings in Insulet were worth $3,884,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Elevation Wealth Partners LLC increased its stake in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares in the last quarter. Activest Wealth Management boosted its position in shares of Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. WPG Advisers LLC boosted its position in shares of Insulet by 169.3% in the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 171 shares in the last quarter. State of Wyoming boosted its position in shares of Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 73 shares in the last quarter. Finally, Continuum Advisory LLC purchased a new stake in shares of Insulet in the 2nd quarter worth approximately $46,000.

Insulet Trading Up 2.3%

NASDAQ:PODD opened at $149.81 on Tuesday. The company’s 50 day moving average price is $142.06 and its 200-day moving average price is $175.98. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 1.25 and a beta of 1.06.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The company had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same period in the previous year, the business earned $1.24 EPS. The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities research analysts forecast that Insulet Corporation will post 6.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PODD shares. Benchmark reduced their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their target price on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Leerink Partners increased their target price on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a research note on Thursday, November 5th. Citigroup raised their price target on Insulet from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Finally, Truist Financial restated a “hold” rating and set a $160.00 price target (up from $153.00) on shares of Insulet in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $185.67.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.